Total Payments
$20,539
2024 Payments
$18,450
Companies
19
Transactions
82
Medicare Patients
1,464
Medicare Billing
$181,567
Payment Breakdown by Category
Other$15,804 (76.9%)
Food & Beverage$3,276 (16.0%)
Travel$1,459 (7.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,804 | 5 | 76.9% |
| Food and Beverage | $3,276 | 69 | 16.0% |
| Travel and Lodging | $1,459 | 8 | 7.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Madrigal Pharmaceuticals | $18,149 | 22 | $0 (2024) |
| ABBVIE INC. | $812.80 | 17 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $219.69 | 2 | $0 (2019) |
| Janssen Biotech, Inc. | $202.85 | 8 | $0 (2024) |
| QOL Medical, LLC | $160.95 | 8 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $146.94 | 4 | $0 (2023) |
| Daiichi Sankyo Inc. | $144.15 | 3 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $115.44 | 1 | $0 (2017) |
| Cook Medical LLC | $110.10 | 1 | $0 (2020) |
| Dova Pharmaceuticals | $108.70 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,450 | 35 | Madrigal Pharmaceuticals ($18,149) |
| 2023 | $503.25 | 21 | Janssen Biotech, Inc. ($89.35) |
| 2022 | $154.10 | 3 | ABBVIE INC. ($130.70) |
| 2021 | $277.25 | 8 | AbbVie Inc. ($245.16) |
| 2020 | $110.10 | 1 | Cook Medical LLC ($110.10) |
| 2019 | $376.50 | 7 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($219.69) |
| 2018 | $244.09 | 3 | Daiichi Sankyo Inc. ($131.48) |
| 2017 | $424.62 | 4 | AbbVie, Inc. ($220.01) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,290.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $30.38 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,548.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $128.94 | General |
| Category: LIVER DISEASE | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | Cash or cash equivalent | $70.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $101.64 | General |
| Category: LIVER DISEASE | ||||||
| 10/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,903.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $103.70 | General |
| Category: LIVER DISEASE | ||||||
| 10/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $24.12 | General |
| Category: LIVER DISEASE | ||||||
| 10/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,548.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $88.44 | General |
| Category: LIVER DISEASE | ||||||
| 10/08/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,515.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $490.70 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $307.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $186.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $127.50 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $80.91 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $77.39 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $65.55 | General |
| Category: LIVER DISEASE | ||||||
| 09/11/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/20/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $17.02 | General |
| Category: THERAPY FOR CSID | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 450 | 480 | $388,418 | $55,574 |
| 2022 | 13 | 426 | 442 | $359,271 | $50,382 |
| 2021 | 9 | 363 | 380 | $325,339 | $47,392 |
| 2020 | 9 | 225 | 240 | $192,189 | $28,219 |
Total Patients
1,464
Total Services
1,542
Medicare Billing
$181,567
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 84 | 84 | $46,536 | $11,425 | 24.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 35 | 36 | $83,880 | $8,716 | 10.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 73 | $26,572 | $8,258 | 31.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 21 | 21 | $30,954 | $3,999 | 12.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 53 | $13,091 | $3,862 | 29.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 31 | 31 | $64,449 | $3,824 | 5.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 32 | 33 | $50,655 | $3,015 | 6.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 33 | 33 | $12,045 | $2,725 | 22.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 13 | 13 | $21,814 | $2,699 | 12.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $10,516 | $2,589 | 24.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 27 | $6,804 | $1,938 | 28.5% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 41 | 42 | $5,166 | $1,295 | 25.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $15,936 | $1,229 | 7.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 78 | 78 | $41,964 | $10,456 | 24.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 31 | 31 | $70,804 | $7,131 | 10.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 65 | $22,945 | $6,714 | 29.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 37 | 37 | $75,406 | $4,706 | 6.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 51 | 51 | $18,054 | $4,600 | 25.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 18 | 18 | $25,704 | $3,754 | 14.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 31 | 31 | $46,655 | $3,263 | 7.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 43 | $10,320 | $2,601 | 25.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 11 | 11 | $17,666 | $2,288 | 12.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $6,032 | $1,444 | 23.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 20 | $4,940 | $1,308 | 26.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $14,973 | $1,172 | 7.8% |
About Dr. Nihar Shah, MD
Dr. Nihar Shah, MD is a Hepatology healthcare provider based in Berkeley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2012. The National Provider Identifier (NPI) number assigned to this provider is 1285998609.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nihar Shah, MD has received a total of $20,539 in payments from pharmaceutical and medical device companies, with $18,450 received in 2024. These payments were reported across 82 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($15,804).
As a Medicare-enrolled provider, Shah has provided services to 1,464 Medicare beneficiaries, totaling 1,542 services with total Medicare billing of $181,567. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Gastroenterology
- Location Berkeley, CA
- Active Since 06/29/2012
- Last Updated 01/29/2021
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1285998609
Products in Payments
- REZDIFFRA (Drug) $18,027
- STELARA (Biological) $318.29
- CREON (Drug) $158.83
- INJECTAFER (Drug) $144.15
- RESMETIROM (Drug) $122.59
- XIFAXAN (Drug) $113.90
- Humira (Biological) $112.61
- Cook Medical Hemostasis (Device) $110.10
- Doptelet (Drug) $108.70
- Mavyret (Drug) $108.14
- DOPTELET (Drug) $105.79
- SUCRAID (Drug) $99.60
- HUMIRA (Biological) $95.26
- OCA (Drug) $89.17
- DUPIXENT (Biological) $88.48
- GI GENIUS (Device) $81.43
- Sucraid (Drug) $61.35
- OCALIVA (Drug) $57.77
- LINZESS (Drug) $54.57
- REBYOTA (Biological) $42.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.